S. aureus-infected patient cohort
| Patient number | Age | Sex | Race | Type of S. aureus infectiona | Treatmentb | Site of infectionc | Sample collection time point after positive culture | Chronicd or recurrente infection? | PB % of total B cells | No. of PB sequences | No. of mAbs generated |
| 002-10-007 | 49 | M | W | S. aureus | Unreported | SSTI | 7 (laboratory infection) | N | 0.30 | 40 | 11 |
| 005-10-015 | - | F | W | S. aureus | Unreported | SSTI | 7 (laboratory infection) | N | 1.70 | 10 | 6 |
| 055-11-077 | 52 | F | - | MSSA | A, L | SSTI | 7 | Y | 0.71 | 56 | - |
| 055-11-080 | 52 | F | - | MSSA | A, L | SSTI | 18 | Y | 1.96 | 49 | - |
| 056-11-078 | 19 | F | - | MSSA | K, M | SSTI | 9 | N | - | - | - |
| 057-11-079 | 68 | F | - | MRSA | V | C | 7 | N | 0.05 | - | - |
| 058-11-081 | 31 | M | - | MSSA | C, S | SSTI | 4 | N | 2.50 | - | - |
| 060-11-083 | 57 | M | - | MRSA | C, B | S | 9 | Y | 0.14 | 53 | 26 |
| 061-11-084 | 63 | F | - | MRSA | B, D, C | SSTI | 8 | N | 1.12 | 56 | 14 |
| 062-11-085f | 34 | F | - | MRSA | S | SSTI | 18 | N | 0.76 | - | - |
| 063-11-090 | 29 | F | - | MSSA | B, C | SSTI | 20 | N | 0.95 | - | - |
| 064-11-092 | 18 | M | - | MRSA | B, D, C | SSTI | 11 | Y | 1.47 | - | - |
| 070-12-001 | 29 | F | W | MSSA | V, An, Ce, O | SSTI and P | 12 | N | 0.56 | 55 | 19 |
| 070-12-002 | 29 | F | W | MSSA | V, An, Ce, O | SSTI and P | 13 | N | 0.26 | - | - |
| 073-11-007 | 46 | M | AA | MSSA | V, Cef, D (Chronically), K | SF | 17 | N | 1.05 | 66 | 26 |
| 075-12-027 | 28 | F | AA | MSSA | C | SSTI | - | N | - | - | - |
| 076-12-038 | 68 | F | W | MSSA | D,T, M | N | 28 | N | - | - | - |
| 082-12-080 | 24 | M | - | MSSA | O, Cef | M/B | >70 d | N | 4.02 | 63 | 32 |
| 084-13-003f | 47 | M | AA/W | MRSA | C, L, D, Cip, Cef, F, Fl, B | SSTI | 3 | N | 1.43 | 45 | - |
| 099-13-102 | 22 | F | W | S. aureus | V | SSTI | - | N | 2.74 | 51 | - |
| Patient number | Age | Sex | Race | Type of S. aureus infectiona | Treatmentb | Site of infectionc | Sample collection time point after positive culture | Chronicd or recurrente infection? | PB % of total B cells | No. of PB sequences | No. of mAbs generated |
| 002-10-007 | 49 | M | W | S. aureus | Unreported | SSTI | 7 (laboratory infection) | N | 0.30 | 40 | 11 |
| 005-10-015 | - | F | W | S. aureus | Unreported | SSTI | 7 (laboratory infection) | N | 1.70 | 10 | 6 |
| 055-11-077 | 52 | F | - | MSSA | A, L | SSTI | 7 | Y | 0.71 | 56 | - |
| 055-11-080 | 52 | F | - | MSSA | A, L | SSTI | 18 | Y | 1.96 | 49 | - |
| 056-11-078 | 19 | F | - | MSSA | K, M | SSTI | 9 | N | - | - | - |
| 057-11-079 | 68 | F | - | MRSA | V | C | 7 | N | 0.05 | - | - |
| 058-11-081 | 31 | M | - | MSSA | C, S | SSTI | 4 | N | 2.50 | - | - |
| 060-11-083 | 57 | M | - | MRSA | C, B | S | 9 | Y | 0.14 | 53 | 26 |
| 061-11-084 | 63 | F | - | MRSA | B, D, C | SSTI | 8 | N | 1.12 | 56 | 14 |
| 062-11-085f | 34 | F | - | MRSA | S | SSTI | 18 | N | 0.76 | - | - |
| 063-11-090 | 29 | F | - | MSSA | B, C | SSTI | 20 | N | 0.95 | - | - |
| 064-11-092 | 18 | M | - | MRSA | B, D, C | SSTI | 11 | Y | 1.47 | - | - |
| 070-12-001 | 29 | F | W | MSSA | V, An, Ce, O | SSTI and P | 12 | N | 0.56 | 55 | 19 |
| 070-12-002 | 29 | F | W | MSSA | V, An, Ce, O | SSTI and P | 13 | N | 0.26 | - | - |
| 073-11-007 | 46 | M | AA | MSSA | V, Cef, D (Chronically), K | SF | 17 | N | 1.05 | 66 | 26 |
| 075-12-027 | 28 | F | AA | MSSA | C | SSTI | - | N | - | - | - |
| 076-12-038 | 68 | F | W | MSSA | D,T, M | N | 28 | N | - | - | - |
| 082-12-080 | 24 | M | - | MSSA | O, Cef | M/B | >70 d | N | 4.02 | 63 | 32 |
| 084-13-003f | 47 | M | AA/W | MRSA | C, L, D, Cip, Cef, F, Fl, B | SSTI | 3 | N | 1.43 | 45 | - |
| 099-13-102 | 22 | F | W | S. aureus | V | SSTI | - | N | 2.74 | 51 | - |
MRSA, methicillin-susceptible S. aureus (MSSA), S. aureus denotes S. aureus infections of unknown β-lactam antibiotic resistance.
Drug key: Augmentin (A), Ancef (An), Bactrim (B), Clindamycin (C), Cefepime (Ce), Cefazolin (Cef), Ciprofloxacin (Cip), Doxycycline (D), Flagyl (F), Fluconazole (Fl), Keflex (K), Linezolid (L), Mupirocin (M), Oxacillin (O), Silvadene (S), Tetracycline (T), Vancomycin (V).
Site of infection key: Conjunctival (C), Bacteremia (B), Muscle (M), Nasal (N), Periosteum (P), Sinus (S), Synovial Fluid (SF), Skin and Soft Tissue Infection (SSTI).
Chronic infections were infections that lasted ≥6 wk.
Recurrent infections were indicated as S. aureus infections following presumed clearance of initial infection presented in this study.
Comments: Patient 062-11-085 had other gram negatives and gram positives in laboratory culture which were treated with (Cip) and Azithromycin. Paitent 084-13-003 diagnosed Onychomycosis treated with (Fl).